Navigation Links
Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP,Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. presented Phase I data of its ADP receptor antagonist at the of Cardiology's (ACC) 56th Annual Scientific Session this week. Portola's reversible antiplatelet compound, PRT060128, appeared safe and well-tolerated in this study and achieved high-level platelet inhibition.

Portola presented the data in a poster session titled "First in Human Experience with PRT060128, a New Direct-acting, Reversible P2Y(12) Inhibitor for IV and Oral Use" which describes the single ascending dose (SAD) study of the oral formulation of PRT060128. In this study, dose dependent and full inhibition of ADP-induced platelet aggregation was achieved. In addition, following administration of PRT060128, inhibition of platelet aggregation was fully reversed within 24 hours post dosing. All doses of PRT060128 were well tolerated. There were no serious adverse events and no discontinuations due to an adverse event.

"Successful results from both our Phase I oral and intravenous studies build a strong foundation for advancing PRT060128 in the clinic," said Dan Gretler, MD, Portola's vice president of Clinical Development and Regulatory Affairs. "We will initiate our Phase II clinical program later this year to further study the differentiated properties of our ADP receptor antagonist."

Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral
'"/>




Page: 1 2

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
3. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Regulatory and Reimbursement Landscape Poland " an essential ... in the healthcare market and provides insights into ... Most importantly, the report provides valuable insights into ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... ... , ... , , , ... ...
... , ... ... ... ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 2Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 3Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 4Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 2An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 3An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 4An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 6
(Date:8/28/2014)... 29, 2014 Top10BestSEOHosting.com has recently ... that FatCow, Hostgator and Bluehost are the best ... ) has been working in the hosting industry ... is connected to multiple GB connections to ensure ... disruptions to customers’ websites. The great thing is ...
(Date:8/28/2014)... 28, 2014 Blood's Thicker Than Water is ... and family ties in the heart of the city. Raymond ... a story about how disrespect caused two families to collide ... streets. , The Yayo Boyz and the M.O.B. Boyz clash ... and local onlookers in a silent terror. "Guerrilla," AKA "Real," ...
(Date:8/28/2014)... Tempe, Ariz. (PRWEB) August 28, 2014 ... Force Impact Technologies , has been named one ... of the Year competition. , This is the fourth ... finalist in the competition. Jared Schoepf, co-founder of SafeSIPP, ... in 2013 and 2012, respectively. In 2011, ASU dominated ...
(Date:8/28/2014)... 2014 (HealthDay News) -- Arguments between parents may damage ... Parents in more than 200 families were asked ... the end of each day, mothers and fathers rated ... their children. On days when parents reported conflict ... children were also strained, according to the study recently ...
(Date:8/28/2014)... August 28, 2014 ABC television stars ... 49th MDA Show of Strength Telethon airing Sunday, Aug. ... to help raise funds and awareness to help save ... by muscle disease. , Viewers tuning into the 2014 ... heart-felt appeals and introductions from some of the network’s ...
Breaking Medicine News(10 mins):Health News:Best Suppliers of Affordable Hosting Products Introduced by Top10BestSEOHosting.com 2Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4
... for what doctors call a life-threatening malignant glioma , , ... Kennedy,s doctors said Monday that they had completed a ... , "I am pleased to report that Senator Kennedy,s ... Friedman said in a statement, the Boston Globe ...
... Alcan Global Pharmaceutical Packaging,part of Rio Tinto Alcan,s ... it will participate in an initiative sponsored by ... the context of World,Environment Day. The theme for ... Low,Carbon Economy", and will be celebrated on June ...
... The world,s largest spa tradeshow and conference, LAS ... Spa Conference (IECSC) Las Vegas will be held on ... Center. Professionals from around the,world will convene at the ... experience the latest products and services, and,learn about the ...
... Healthcare Advertising Marketing Awards, INDIANAPOLIS, June ... over 4,400,entries, the 25th Annual Healthcare Advertising ... Indianapolis and St. Vincent Hospital for its,creative ... Additionally, both entities won three silver (Total ...
... following event,announcement was released by the Association for ... Association for Professionals in Infection Control and Epidemiology,(APIC,s) ... WHEN:, Sunday - Thursday, June 15-19, 2008, ... 700 14th Street (Directions, http://www.denverconvention.com/about-directions.htm ), ...
... Animal Dermatology Clinic (ADC) - San,Diego announces ... the,American College of Veterinary Dermatology (ACVD)., Dr. ... degree,from the University of California, Davis in 2001. ... VCA Emergency Animal Hospital,and Referral Center in San ...
Cached Medicine News:Health News:Sen. Kennedy's Brain Tumor Surgery Called a 'Success' 2Health News:Sen. Kennedy's Brain Tumor Surgery Called a 'Success' 3Health News:Sen. Kennedy's Brain Tumor Surgery Called a 'Success' 4Health News:The second year of participation for Alcan Global Pharmaceutical Packaging in World Environment Day 2Health News:International Esthetics, Cosmetics & Spa Conference - Las Vegas 2Health News:International Esthetics, Cosmetics & Spa Conference - Las Vegas 3Health News:Publicis Indianapolis and St. Vincent Hospital Win the Gold 2Health News:Animal Dermatology Clinic - San Diego Announces Dr. Brett Wildermuth, DVM, Achieves Diplomate Status With the American College of Veterinary Dermatology 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: